Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹7 Cr
Revenue (TTM)
₹0 Cr
Net Profit (TTM)
₹0 Cr
ROE
0 %
ROCE
0 %
P/E Ratio
--
P/B Ratio
-4.5
Industry P/E
44.74
EV/EBITDA
-2184.3
Div. Yield
0 %
Debt to Equity
-1
Book Value
₹--
EPS
₹-0.1
Face value
10
Shares outstanding
5,850,000
CFO
₹-8.40 Cr
EBITDA
₹-2.23 Cr
Net Profit
₹-8.92 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Adline Chem Lab
| 35.7 | -11.0 | 56.6 | -10.4 | 32.3 | 19.5 | -- |
|
BSE Healthcare*
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2022
|
|---|---|---|
|
Adline Chem Lab
| -58.6 | -25.8 |
|
BSE Small Cap
| -6.6 | -1.8 |
|
BSE Healthcare
| -3.3 | -12.1 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Adline Chem Lab
|
12.5 | 7.3 | 0.0 | -0.1 | -- | -- | -- | -4.5 |
| 2,110.2 | 17,282.6 | 1,215.1 | 284.8 | 28.7 | 21.1 | 60.2 | 11.4 | |
| 656.2 | 12,893.6 | 7,266.8 | 627.5 | 11.9 | 12.6 | 20.5 | 2.4 | |
| 613.6 | 15,214.7 | 5,092.5 | 545.5 | 15.9 | 14.1 | 27.9 | 3.7 | |
| 839.3 | 13,375.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 30.9 | 2.0 | |
| 1,027.6 | 18,409.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 11.8 | 2.1 | |
| 1,404.5 | 16,092.2 | 1,419.3 | 20.1 | 8.4 | 0.5 | 800.5 | 2.8 | |
| 142.2 | 18,882.0 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.4 | |
| 391.1 | 15,752.9 | 3,720.2 | 352.1 | 13.7 | 8.2 | 44.7 | 3.3 | |
| 1,271.5 | 20,670.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 939.6 | 4.5 |
No Review & Analysis are available.
Kamron Laboratories Ltd markets pharmaceutical products, and nutraceuticals and dietary supplements in India and internationally. It provides tablets, capsules, and injections. The company provides its products for anti-anxiety, anti-infective, bone... health, gastroentology care, hemostatic, multi-vitamins, pediatric care, pain and inflammation, pregnancy and reproductive care, respiratory care, and hepatocare. It also offers veterinary products and educational supplements. The company was founded in 1988 and is based in Gandhinagar, India. Read more
Incorporated
1988
Chairman
--
Managing Director
Sarang Pathak
Headquarters
Ahmedabad, Gujarat
Website
Looking for more details about Adline Chem Lab Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Adline Chem Lab Ltd is ₹12.50 (BSE) as of 16-Mar-2026 IST. Adline Chem Lab Ltd has given a return of 32.28% in the last 3 years.
Since, TTM earnings of Adline Chem Lab Ltd is negative, P/E ratio is not available.
The P/B ratio of Adline Chem Lab Ltd is -4.54 times as on 16-Mar-2026, a 246 discount to its peers’ median range of 3.10 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
-5.20
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
-2.02
|
|
2022
|
5.35
|
1.45
|
|
2021
|
0.00
|
1.55
|
The 52-week high and low of Adline Chem Lab Ltd are Rs 19.08 and Rs 7.60 as of 03-Apr-2026.
Adline Chem Lab Ltd has a market capitalisation of ₹ 7 Cr as on 16-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Adline Chem Lab Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹-0.16
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.